The future of imaging in drug discovery

Journal of Clinical Pharmacology

Volumn 39, Issue 8 SUPPL., 1999, Pages

  Schmidt, Mark E ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG SCREENING; FORECASTING; HUMAN; METHODOLOGY; PHARMACEUTICS; REVIEW;

DIAGNOSTIC IMAGING; DRUG EVALUATION; FORECASTING; HUMANS; TECHNOLOGY, PHARMACEUTICAL; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033175944     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1999.tb05938.x     Document Type: Article

References (21)

1. Sokoloff L: Cerebral circulation, energy metabolism, and protein synthesis: general characteristics and principles of measurement, in: Phelps ME, Mazziota JC, Schelbert HR (eds.): Positron Emission Tomography: Principles and Applications for the Brain and Heart. New York: Raven, 1986;1-73.
2. Stein E, Pankiewicz J, Harsch H, Cho J, Fuller S, Hoffman R, Hawkins M, Rao S, Bandettini P, Bloom A: Nicotine-induced limbic cortical activation in the human brain: a functional MRI study. Am J Psychiatry 1998;155:1009-1015.
3. Grasby PM, Frith CD, Paulesu E, Friston KJ, Frackowiak RS, Dolan RJ: The effect of the muscarinic antagonist scopolamine on regional cerebral blood flow during the performance of a memory task. Experimental Brain Research 1995;104:337-348.
4. Blin J, Ivanoiu A, Coppens A, De Volder A, Labar D, Michel C, Laterre EC: Cholinergic neurotransmission has different effects on cerebral glucose consumption and blood flow in young normals, aged normals, and Alzheimer's disease patients. Neuroimage 1997;6:335-343.
5. Gee A: Mapping second messenger activation in the brain. Paper presented at NeuroreceptorMapping98, Second International Symposium on Functional Neuroreceptor Mapping of Living Brain, June 1998, Ann Arbor, MI.
6. Small G, Mazziotta J, Collins M, Baxter L, Phelps M, Mandelkern M, Kaplan A, La Rue A, Adamson C, Chang L, Guze B, Corder E, Saunders A, Haines J, Pericak-Vance M, Roses A: Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995;273:942-947.
7. Baird A, Warach S: Magnetic resonance imaging of acute stroke. Journal of Cerebral Blood Flow and Metabolism 1998;18:583-609.
8. Osman O, Rudorfer M, Potter W: Idazoxan: a selective alpha 2-antagonist and effective sustained antidepressant in two bipolar depressed patients. Archives of General Psychiatry 1989;46:958-959.
9. 2-blockade by idazoxan. Clin Pharmacol Ther 1995;57:684-695.
10. Brooks R, Di Chiro G, Zukerberg B, Bairamian D, Larson SM: Test-retest studies of cerebral glucose metabolism using fluorine-18 deoxyglucose: validation of method. J Nucl Med 1987;28:53-59.
11. Schmidt M, Ernst M, Matochik J, Maisog J, Pan B, Zametkin A, Potter W: Cerebral glucose metabolism during pharmacologic studies: test-retest under placebo conditions. J Nucl Med 1996;37:1142-1149.
12. 2-adrenoceptor blockade by idazoxan in healthy male and female volunteers. Psychoneuroendocrinology 1997;22:177-188.
13. Schmidt M, Matochik J, Goldstein D, Schouten J, Zametkin A, Potter W: Gender differences in brain metabolic and plasma catecholamine responses to alpha2-adrenoceptor blockade. Neuropsychopharmacology 1997;16:298-310.
14. 3H] p-aminoclonidine. Eur J Pharmacol 1984;106:477-488.
15. Davidson L, Vandongen R, Rouse IL, Beilin LJ, Tunney A: Sex-related differences in resting and stimulated plasma noradrenaline and adrenaline. Clin Sci 1984;67:347-352.
16. Bremner JD, Innis Rb, Ng Ck, Staib LH, Salamon Rm, Bronen Ra, Duncan J, Southwick SM, Krystal JH, Rich D, Zubal G, Dey H, Soufer R, Charney DS: Positron emission tomography measurement of cerebral metabolic correlates of yohimbine administration in combatrelated posttraumatic stress disorder. Arch Gen Psychiatry 1997;54:246-254.
17. Moghaddam B, Adams B: Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998;281:1349-1352.
18. Lam AGM, Lodge D, McCulloch J: Effects of the selective group II metabotropic glutamate receptor agonist LY354740 on energy metabolism in the rat brain. Soc Neurosci Ab 1997;23:790.2
19. Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G: Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biological Psychiatry 1993;33:227-235.
20. Koepp MJ, Gunn Rn, Lawrence Ad, Cunningham VJ, Dagher A, Jones T, Brooks DJ, Bench CJ, Grasby PM: Evidence for striatal dopamine release during a video game. Nature 1998;393:266-268.
21. Heller M, Eisenberg R: Can patents deter innovation? The anti-commons in biomedical research. Science 1998;280:698-701.